LQDA

AI MemoPost-earnings T+3

Liquidia

As of 2026-05-14/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-14 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

2026 PH-ILD and franchise-expansion study progress • 2026-08-12

Expected move: +2%

Biggest risk

The main bear pushback is that much of the near-term upside may already be absorbed after the earnings reset: by May 13, 2026 the stock closed at $57.59, already around the revised target band visible in secondary coverage and well above the stale packet median. That leaves less room for multiple expansion if launch growth moderates, PH-ILD study progress slips, or litigation risk re-enters focus.

Invalidation

Break below $38 or thesis failure.

What would change my mind?

The post-earnings read-through improved: secondary follow-up coverage indicated Q1 revenue and EPS beat consensus, and at least two analysts reportedly raised targets to about $59-$60 after the print, which is more constructive than the stale packet median target of $45.7. The main bull argument is that YUTREPIA launch depth, prescriber expansion, and positive EBITDA are arriving faster than a typical small-cap biopharma commercialization curve.

Research note

Recommendation

—

Confidence

medium

As of

2026-05-14

Base target

$56

p=45%

Bull target

$68

p=30%

Bear target

$38

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 earnings reset around YUTREPIA commercial strength
Self-funded commercial scale can support broader pipeline spend
The post-earnings read-through improved: secondary follow-up coverage indicated Q1 revenue and EPS beat consensus, and at least two analysts reportedly raised targets to about $59-$60 after the print, which is more constructive than the stale packet median target of $45.7.

BearKey bullets

Commercial expectations are now higher after a strong Q1; sustaining launch growth at a much larger revenue base is harder, especially as SG&A rose materially with the commercial buildout [#8-K-2026-05-11].
R&D expense increased with L606 and YUTREPIA development activity, so any pipeline delay or weaker launch productivity could compress the current self-funded narrative [#8-K-2026-05-11].
The 10-Q notes higher interest expense tied to larger borrowings under the revenue interest financing agreement, adding some balance-sheet sensitivity if growth expectations soften [#10-Q-2026-05-11].

WatchKey bullets

2026 PH-ILD and franchise-expansion study progress

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $56 (p=45%)

Bull/Bear spread: +23% / -31%

Vs latest close: Bull +23% · Base +2% · Bear -31%

Scenario probabilities

Bull Target: $68 (p=30%)Base Target: $56 (p=45%)Bear Target: $38 (p=25%)

Commentary

Post-earnings tone is positive but no longer early. Company-source evidence clearly improved on May 11, 2026, and secondary coverage framed the print as a revenue/EPS beat with modestly positive immediate price reaction. By the May 13, 2026 anchor close of $57.59, however, the stock had already moved to around the revised analyst target area seen in secondary follow-ups, while broad sell-side revision coverage still looks thin. That keeps the setup constructive but better described as a monitored high-expectation name than a fresh undiscovered re-rating.

As of 2026-05-14 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 earnings reset around YUTREPIA commercial strength
Self-funded commercial scale can support broader pipeline spend

Scenarios

Bull Target (Scenario probability)

$68 / p=30% prob

Base Target (Scenario probability)

$56 / p=45% prob

Bear Target (Scenario probability)

$38 / p=25% prob

Price $55 as of 2026-06-02

Nearest Scenario: Base (∆ 2%)

Targets vs latest close: Bull +23% · Base +2% · Bear -31%

Sentiment & Exposure

News Sentiment (30d)

0.68

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-12
2026 PH-ILD and franchise-expansion study progress
The company presentation filed with the May 11, 2026 8-K said Liquidia is recruiting ASCENT Cohort B Tyvaso transition patients and recruiting the global Phase 3 Re-Spire study for L606 in PH-ILD while advancing IPF/PPF, PH-COPD, and SSc-Raynaud's programs; credible enrollment or execution progress could extend the story beyond the initial YUTREPIA launch [#8-K-2026-05-11].
Prob 55.00% • Move 13.00% • Priced-in 34.00%

Short-term Catalysts

Next few weeks

Q1 earnings reset around YUTREPIA commercial strength
2026-05-11
Q1 results attached to the May 11, 2026 8-K showed YUTREPIA net product sales of about $129.9M, roughly 44% Q/Q growth, third consecutive quarter of profitability, and cash rising to $222.8M; management also disclosed more than 4,500 unique prescriptions and about 3,750 treated patients since launch, which materially strengthened the near-term earnings base [#8-K-2026-05-11].
Prob 80% • Move 9% • Priced-in 72%

Long-term Catalysts

Months to a year

Self-funded commercial scale can support broader pipeline spend
2026-12-31
Liquidia's Q1 release and 10-Q showed profitability, $222.8M of cash at March 31, 2026, and higher R&D spending driven partly by L606 and YUTREPIA development work, supporting a view that the company can fund broader prostacyclin franchise expansion without an immediate financing need, though the setup still depends on sustaining launch momentum [#8-K-2026-05-11] [#10-Q-2026-05-11].
Prob 64% • Move 15% • Priced-in 53%

Risks

Commercial expectations are now higher after a strong Q1; sustaining launch growth at a much larger revenue base is harder, especially as SG&A rose materially with the commercial buildout [#8-K-2026-05-11].
R&D expense increased with L606 and YUTREPIA development activity, so any pipeline delay or weaker launch productivity could compress the current self-funded narrative [#8-K-2026-05-11].
The 10-Q notes higher interest expense tied to larger borrowings under the revenue interest financing agreement, adding some balance-sheet sensitivity if growth expectations soften [#10-Q-2026-05-11].
The May 2026 corporate presentation says United Therapeutics is seeking injunctive relief in ongoing litigation that could block Liquidia's ability to continue selling YUTREPIA for one or both of PAH and PH-ILD [#8-K-2026-05-11].

Peers

Symbol	Summary
APLS	Packet-listed same-sector mid-cap peer candidate; useful as a commercial-stage biotech comp, but not a direct inhaled prostacyclin comparator.
CRSP	Packet-listed same-sector mid-cap peer candidate; more pipeline-heavy than Liquidia and therefore a looser valuation/risk benchmark.
LEGN	Packet-listed same-sector mid-cap peer candidate; commercial-plus-pipeline biotech comp, but not indication-matched to PAH/PH-ILD.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-14

AI Stock Memo: LQDA - Liquidia - RankAlpha